Keywords
Organic Gastrointestinal Disorders
Bile Acid Diarrhea
Diarrhea-predominant IBS
Small Intestinal Bacterial Overgrowth
How to Cite
Abstract
Introduction: Organic gastrointestinal (GI) disorders can be missed in individuals with irritable bowel syndrome (IBS). This study investigated the frequency of organic disorders in patients with diarrhea-predominant IBS or functional diarrhea and the impact of treatment for any identified alternative diagnoses.
Methods: Between April 2019 and March 2020, the results of comprehensive investigations, including blood and fecal tests, a 75selenium homophobic acid taurine scan, a breath test, and endoscopies performed on consecutive eligible patients, were recorded. Symptom burden was reassessed after treatment for any GI conditions identified.
Results: 66 (15 males) consecutive patients were included. Two patients (3%) were diagnosed with colonic malignancy; 21 (38%) had bile acid diarrhea; one (1%) had pancreatic exocrine insufficiency; and 31 (54%) had small intestinal bacterial overgrowth. 21 patients (32%) had at least two GI diagnoses. Significant improvement in symptoms occurred following treatment (p<0.0001).
Conclusions: Multiple co-existing conditions were detected in many of these patients, with one-third of the cohort having more than one abnormal test. When these alternative diagnoses were treated, patients reported significant symptomatic improvement. Larger studies are required to validate our findings, and these patients' investigative and management pathways should be amended accordingly.
References
1. Poon D, Law GR, Major G, Andreyev HJN. A systematic review and meta-analysis on the prevalence of non-malignant, organic gastrointestinal disorders misdiagnosed as irritable bowel syndrome. Sci Rep. 2022: 1949 [PMID: 35121775, https://doi.org/10.1038/s41598-022-05933-1]
2. Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988: 129 [PMID: 3123181, https://doi.org/10.1007/BF01535722]
3. Wiklund IK, Fullerton S, Hawkey CJ, Jones RH, Longstreth GF, Mayer EA, Peacock RA, Wilson IK, Naesdal J. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol. 2003: 947 [PMID: 14531531, https://doi.org/10.1080/00365520310004209]
4. Kulich KR, Madisch A, Pacini F, Pique JM, Regula J, Van Rensburg CJ, Ujszaszy L, Carlsson J, Halling K, Wiklund IK. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes. 2008: 12 [PMID: 18237386, https://doi.org/10.1186/1477-7525-6-12]
5. Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L, Covington PS. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med. 2016: 242 [PMID: 26789872, https://doi.org/10.1056/NEJMoa1505180]
6. Barberio B, Houghton LA, Yiannakou Y, Savarino EV, Black CJ, Ford AC. Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. Am J Gastroenterol. 2021: 362 [PMID: 33009062, https://doi.org/10.14309/ajg.0000000000000946]
7. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993: 791 [PMID: 8329970, https://doi.org/10.1111/j.1360-0443.1993.tb02093.x]
8. Watson L, Lalji A, Bodla S, Muls A, Andreyev HJ, Shaw C. Management of bile acid malabsorption using low-fat dietary interventions: a useful strategy applicable to some patients with diarrhoea-predominant irritable bowel syndrome? Clin Med (Lond). 2015: 536 [PMID: 26621941, https://doi.org/10.7861/clinmedicine.15-6-536]
9. Jackson A, Lalji A, Kabir M, Muls A, Gee C, Vyoral S, Shaw C, Andreyev HJN. The efficacy of a low-fat diet to manage the symptoms of bile acid malabsorption - outcomes in patients previously treated for cancer. Clin Med (Lond). 2017: 412 [PMID: 28974589, https://doi.org/10.7861/clinmedicine.17-5-412]
10. Gupta A, Muls AC, Lalji A, Thomas K, Watson L, Shaw C, Andreyev HJ. Outcomes from treating bile acid malabsorption using a multidisciplinary approach. Support Care Cancer. 2015: 2881 [PMID: 25693765, https://doi.org/10.1007/s00520-015-2653-5]
11. Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013: 925 [PMID: 24004101, https://doi.org/10.1111/apt.12479]
12. Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010: 547 [PMID: 19996983, https://doi.org/10.1097/MCG.0b013e3181c64c90]
13. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009: 707 [PMID: 19570102, https://doi.org/10.1111/j.1365-2036.2009.04081.x]
14. Phillips ME, Hopper AD, Leeds JS, Roberts KJ, McGeeney L, Duggan SN, Kumar R. Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterol. 2021: [PMID: 34140324, https://doi.org/10.1136/bmjgast-2021-000643]
15. Kurien M, Thurgar E, Davies A, Akehurst R, Andreyev J. Challenging current views on bile acid diarrhoea and malabsorption. Frontline Gastroenterol. 2018: 92 [PMID: 29588835, https://doi.org/10.1136/flgastro-2017-100808]
16. Mathew A, Fernandes D, Andreyev HJN. What is the significance of a faecal elastase-1 level between 200 and 500mug/g? Frontline Gastroenterol. 2023: 371 [PMID: 37581180, https://doi.org/10.1136/flgastro-2022-102271]
17. Struyvenberg MR, Martin CR, Freedman SD. Practical guide to exocrine pancreatic insufficiency - Breaking the myths. BMC Med. 2017: 29 [PMID: 28183317, https://doi.org/10.1186/s12916-017-0783-y]
18. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017: 775 [PMID: 28323273, https://doi.org/10.1038/ajg.2017.46]
19. Williams RE, Black CL, Kim HY, Andrews EB, Mangel AW, Buda JJ, Cook SF. Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. Aliment Pharmacol Ther. 2006: 1667 [PMID: 16696818, https://doi.org/10.1111/j.1365-2036.2006.02928.x]
20. Talley NJ, Zinsmeister AR, Melton LJ, 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol. 1995: 76 [PMID: 7785677, https://doi.org/10.1093/oxfordjournals.aje.a117548]
21. Akehurst RL, Brazier JE, Mathers N, O'Keefe C, Kaltenthaler E, Morgan A, Platts M, Walters SJ. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002: 455 [PMID: 12093301, https://doi.org/10.2165/00019053-200220070-00003]
22. Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K, Jhingran P, Barghout V, Feld AD. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol. 2001: 3122 [PMID: 11721759, https://doi.org/10.1111/j.1572-0241.2001.05258.x]
23. Pare P, Gray J, Lam S, Balshaw R, Khorasheh S, Barbeau M, Kelly S, McBurney CR. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006: 1726 [PMID: 17157129, https://doi.org/10.1016/j.clinthera.2006.10.010]
24. Muller-Lissner SA, Pirk O. Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol. 2002: 1325 [PMID: 12468953, https://doi.org/10.1097/00042737-200212000-00007]
25. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, Frech F, Ofman JJ. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol. 2003: 600 [PMID: 12650794, https://doi.org/10.1111/j.1572-0241.2003.07296.x]
26. Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther. 1997: 1019 [PMID: 9663824, https://doi.org/10.1046/j.1365-2036.1997.00262.x]
27. Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion. 1999: 77 [PMID: 9892803, https://doi.org/10.1159/000007593]
28. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006: 21 [PMID: 16445300, https://doi.org/10.2165/00019053-200624010-00002]
29. Dean BB, Aguilar D, Barghout V, Kahler KH, Frech F, Groves D, Ofman JJ. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005: S17 [PMID: 15926760,
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 ASIDE Gastroenterology